JP2018517410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517410A5 JP2018517410A5 JP2017562027A JP2017562027A JP2018517410A5 JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5 JP 2017562027 A JP2017562027 A JP 2017562027A JP 2017562027 A JP2017562027 A JP 2017562027A JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- domain
- nucleic acid
- protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 15
- 230000019491 signal transduction Effects 0.000 claims description 14
- 102000014400 SH2 domains Human genes 0.000 claims description 12
- 108050003452 SH2 domains Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 9
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 6
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 claims description 3
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 44
- 102000037865 fusion proteins Human genes 0.000 description 19
- 108020001507 fusion proteins Proteins 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000003607 modifier Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 5
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 5
- 102000027596 immune receptors Human genes 0.000 description 5
- 108091008915 immune receptors Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- -1 BTLA4 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 1
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 1
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 1
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 1
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1509413.9A GB201509413D0 (en) | 2015-06-01 | 2015-06-01 | Fusion protein |
| GB1509413.9 | 2015-06-01 | ||
| PCT/GB2016/051576 WO2016193696A1 (en) | 2015-06-01 | 2016-05-31 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086590A Division JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517410A JP2018517410A (ja) | 2018-07-05 |
| JP2018517410A5 true JP2018517410A5 (enExample) | 2019-05-09 |
| JP6833727B2 JP6833727B2 (ja) | 2021-02-24 |
Family
ID=53677545
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562027A Active JP6833727B2 (ja) | 2015-06-01 | 2016-05-31 | 細胞 |
| JP2020086590A Withdrawn JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
| JP2022032551A Withdrawn JP2022066380A (ja) | 2015-06-01 | 2022-03-03 | 細胞 |
| JP2024137629A Pending JP2024149818A (ja) | 2015-06-01 | 2024-08-19 | 細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086590A Withdrawn JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
| JP2022032551A Withdrawn JP2022066380A (ja) | 2015-06-01 | 2022-03-03 | 細胞 |
| JP2024137629A Pending JP2024149818A (ja) | 2015-06-01 | 2024-08-19 | 細胞 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11345734B2 (enExample) |
| EP (2) | EP3730609A1 (enExample) |
| JP (4) | JP6833727B2 (enExample) |
| KR (1) | KR102275460B1 (enExample) |
| CN (1) | CN107667170B (enExample) |
| AU (1) | AU2016272457B2 (enExample) |
| BR (1) | BR112017023190A2 (enExample) |
| CA (1) | CA2986956C (enExample) |
| CL (1) | CL2017003057A1 (enExample) |
| DK (1) | DK3303568T3 (enExample) |
| ES (1) | ES2791338T3 (enExample) |
| GB (1) | GB201509413D0 (enExample) |
| HU (1) | HUE050132T2 (enExample) |
| IL (1) | IL255594B (enExample) |
| MX (1) | MX383118B (enExample) |
| PL (1) | PL3303568T3 (enExample) |
| PT (1) | PT3303568T (enExample) |
| RU (1) | RU2729158C2 (enExample) |
| WO (1) | WO2016193696A1 (enExample) |
| ZA (1) | ZA201707334B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN108025024B (zh) | 2015-07-28 | 2022-11-29 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
| BR112018013679A2 (pt) | 2016-01-11 | 2019-01-22 | Univ Leland Stanford Junior | proteínas quiméricas e métodos de regulação de expressão gênica |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| GB201621889D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Cell |
| US20230159619A1 (en) * | 2017-02-23 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Compositions and methods for regulating immune system activity |
| EP3589647A1 (en) * | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| GB201707783D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| AU2018270078A1 (en) * | 2017-05-15 | 2019-11-07 | Autolus Limited | A cell comprising a chimeric antigen receptor (CAR) |
| US20200306303A1 (en) * | 2017-09-29 | 2020-10-01 | Chiou Hwa YUH | Methods and compositions enhancing survival and functionality of anti-tumor and anti-viral t cells |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| WO2019118518A2 (en) * | 2017-12-11 | 2019-06-20 | Senti Biosciences, Inc. | Inducible cell receptors for cell-based therapeutics |
| EP3810753A1 (en) * | 2018-06-19 | 2021-04-28 | Autolus Limited | Cell |
| CN109294982B (zh) * | 2018-09-30 | 2020-11-06 | 北京鼎成肽源生物技术有限公司 | 一种rff2细胞 |
| WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| US12454562B2 (en) | 2018-12-06 | 2025-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatable cell surface receptors and related compositions and methods |
| GB201820157D0 (en) * | 2018-12-11 | 2019-01-23 | Imperial Innovations Ltd | Method of treatment |
| WO2020152197A1 (en) | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| JP7602475B2 (ja) | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| EP3938387A1 (en) * | 2019-03-15 | 2022-01-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| JP2022531461A (ja) * | 2019-05-07 | 2022-07-06 | モデルナティエックス インコーポレイテッド | 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法 |
| CN112279923B (zh) * | 2019-07-22 | 2023-07-18 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
| US20220401537A1 (en) * | 2019-09-16 | 2022-12-22 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| US20230151373A1 (en) * | 2019-10-23 | 2023-05-18 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Chimeric polypeptide for regulating immune cells |
| WO2021096868A1 (en) * | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| BR112022011399A2 (pt) | 2019-12-11 | 2022-08-30 | A2 Biotherapeutics Inc | Receptor de antígeno quimérico baseado em lilrb1 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US20230100000A1 (en) | 2020-02-04 | 2023-03-30 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| US12286465B2 (en) | 2020-05-28 | 2025-04-29 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| WO2021263211A2 (en) * | 2020-06-25 | 2021-12-30 | Houston Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| HUE067417T2 (hu) | 2020-08-20 | 2024-10-28 | A2 Biotherapeutics Inc | Készítmények és módszerek EGFR-pozitív rákok kezelésére |
| CN116724052A (zh) | 2020-08-20 | 2023-09-08 | A2生物治疗股份有限公司 | 用于治疗ceacam阳性癌症的组合物和方法 |
| MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
| US20250019740A1 (en) * | 2020-10-26 | 2025-01-16 | Board Of Regents, The University Of Texas System | Mutant proteases and uses thereof |
| AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022096664A1 (en) | 2020-11-09 | 2022-05-12 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
| CN114807042B (zh) * | 2021-01-22 | 2024-09-03 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| JP2023008482A (ja) | 2021-07-06 | 2023-01-19 | 日本たばこ産業株式会社 | たばこ製品の香味料担持構成部材及びこの製造方法 |
| WO2023044304A1 (en) * | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US20250235477A1 (en) | 2021-10-06 | 2025-07-24 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| JP2024540058A (ja) * | 2021-11-04 | 2024-10-31 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 誘導性クラスターキメラ抗原受容体（ｃｃａｒ）構築物の開発 |
| EP4602171A1 (en) | 2022-10-15 | 2025-08-20 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| CN119331105B (zh) * | 2024-09-03 | 2025-10-28 | 中国人民解放军空军军医大学 | 靶向多种免疫检查点的通用多肽-protac及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| CA2223402C (en) * | 1995-06-07 | 2012-07-31 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
| JP2000506007A (ja) | 1996-02-23 | 2000-05-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 細胞によるアッセイ |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| US7060506B2 (en) | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| CN102070719A (zh) * | 2010-11-24 | 2011-05-25 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47 |
| EP4098275A1 (en) * | 2013-03-15 | 2022-12-07 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| HUE060047T2 (hu) * | 2014-10-09 | 2023-01-28 | Univ Yamaguchi | CAR expressziós vektor és CAR-t expresszáló T-sejtek |
| GB201620070D0 (en) | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| GB201717524D0 (en) * | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| JP7602475B2 (ja) | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| GB202007044D0 (en) * | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
-
2015
- 2015-06-01 GB GBGB1509413.9A patent/GB201509413D0/en not_active Ceased
-
2016
- 2016-05-31 ES ES16726416T patent/ES2791338T3/es active Active
- 2016-05-31 DK DK16726416.7T patent/DK3303568T3/da active
- 2016-05-31 PL PL16726416T patent/PL3303568T3/pl unknown
- 2016-05-31 HU HUE16726416A patent/HUE050132T2/hu unknown
- 2016-05-31 CN CN201680030192.8A patent/CN107667170B/zh active Active
- 2016-05-31 RU RU2017145074A patent/RU2729158C2/ru active
- 2016-05-31 EP EP20166710.2A patent/EP3730609A1/en not_active Withdrawn
- 2016-05-31 BR BR112017023190A patent/BR112017023190A2/pt not_active Application Discontinuation
- 2016-05-31 AU AU2016272457A patent/AU2016272457B2/en active Active
- 2016-05-31 KR KR1020177033957A patent/KR102275460B1/ko active Active
- 2016-05-31 PT PT167264167T patent/PT3303568T/pt unknown
- 2016-05-31 EP EP16726416.7A patent/EP3303568B1/en active Active
- 2016-05-31 JP JP2017562027A patent/JP6833727B2/ja active Active
- 2016-05-31 MX MX2017014630A patent/MX383118B/es unknown
- 2016-05-31 CA CA2986956A patent/CA2986956C/en active Active
- 2016-05-31 US US15/577,378 patent/US11345734B2/en active Active
- 2016-05-31 WO PCT/GB2016/051576 patent/WO2016193696A1/en not_active Ceased
-
2017
- 2017-10-27 ZA ZA2017/07334A patent/ZA201707334B/en unknown
- 2017-11-12 IL IL255594A patent/IL255594B/en active IP Right Grant
- 2017-11-30 CL CL2017003057A patent/CL2017003057A1/es unknown
-
2020
- 2020-05-18 JP JP2020086590A patent/JP2020115898A/ja not_active Withdrawn
-
2021
- 2021-11-12 US US17/525,244 patent/US20220267404A1/en active Pending
-
2022
- 2022-03-03 JP JP2022032551A patent/JP2022066380A/ja not_active Withdrawn
-
2024
- 2024-08-19 JP JP2024137629A patent/JP2024149818A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517410A5 (enExample) | ||
| RU2017145074A (ru) | Клетка | |
| EP3749338B1 (en) | Humanized bcma antibody and bcma-car-t cells | |
| Shiratori et al. | Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor | |
| CA3132375A1 (en) | Prostate-specific membrane antigen cars and methods of use thereof | |
| JP2016538855A5 (enExample) | ||
| JP2016538854A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| US20210403885A1 (en) | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy | |
| JP2023517940A (ja) | Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法 | |
| JP7602803B2 (ja) | Ｃｄ１４７キメラ抗原受容体および使用の方法 | |
| JP2019535292A5 (enExample) | ||
| JP7728477B2 (ja) | 抗ｒｏｒ１抗体及びｒｏｒ１を標的とする操作された細胞 | |
| JP6842688B2 (ja) | キメラ抗原受容体 | |
| WO2025016450A1 (en) | Combination of cldn18.2 and gucy2c targeted antagonist therapy | |
| JP7054181B2 (ja) | キメラ抗原受容体 | |
| WO2025134168A1 (en) | Genetically modified immune cells for the treatment of tumors and autoimmune diseases | |
| HK40075954A (en) | Disrupting tumor tissues by targeting fibroblast activation protein (fap) | |
| GB2569692A (en) | T cell antigen receptor chimera | |
| BR122025000772A2 (pt) | Célula | |
| NZ737662B2 (en) | Cell |